mynth
← DATABASE
08/2025100%

Karo Healthcare acquired by KKR

SWEDEN Consumer Products / Personal & Household / Hygiene & Beauty Brands EV €1–10bn

Context

KKR has finalized the 100% acquisition of Karo Healthcare from the EQT VIII fund in a transaction initially announced in April 2025. The strategic rationale for KKR is to capitalize on a pan-European platform already structured for significant scale. Following a period where revenues quadrupled under EQT, Karo is entering an international acceleration phase. KKR plans to leverage its global footprint to deepen Karo’s reach across new distribution channels and geographies, while continuing to consolidate the fragmented sector through targeted bolt-on acquisitions. The transaction was advised by Citigroup and J.P. Morgan for KKR, and Morgan Stanley and Jefferies for EQT.

The acquisition of Karo Healthcare is part of the growth strategy of KKR, which already has several external growth operations under its belt, notably Spectris in 2025.

Karo Healthcare, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Retail & Consumer market trends

Target

Karo Healthcare is a leading European platform specialized in over-the-counter (OTC) consumer healthcare products. Under EQT's ownership, the company underwent a radical transformation, evolving from a Nordic specialty pharma player into a pan-European champion. Its portfolio focuses on trusted brands in resilient categories: Skin Health, Foot Health, Intimate Health, Digestive Health, and Vitamins, Minerals & Supplements (VMS). Present in over 90 countries, Karo relies on a highly digitized commercial platform and a mixed growth model combining organic performance with an aggressive "Buy-and-Build" strategy, evidenced by eight acquisitions completed since 2019.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2024
€450–900M
€100–200M
[members only]
2023
€450–900M
€100–200M
[members only]

Other operations with KKR

Other operations with KKR
DateAcquirerTargetCountrySector
07/2026KKR / ENERGY CAPITAL PARTNERSDCC ENERGYIRELANDDownstream (Refining & Retail)
12/2025KKRWELLASWITZERLANDHygiene & Beauty Brands
07/2025KKRSPECTRISUNITED KINGDOMLab & Scientific Equipment
11/2024KKRGREENVOLTPORTUGALSolar / PV
10/2024KKR / KREFELDANJAC BEAUTY & HEALTHFRANCECDMO
10/2024ORANGE / CINVEN / KKRMASORANGESPAINOperators
06/2024KKRENCAVISGERMANYSolar / PV
10/2023KKRCIRCOR INTERNATIONALUNITED STATESValves, Pumps & Taps
07/2023KKR / MUBADALACOOLIT SYSTEMSCANADAServers & Networks
12/2022KKRAPRILFRANCEBrokerage

Similar deals in Consumer Products

Similar deals in Consumer Products
DateAcquirerTargetCountrySector
10/2025ID UNLIMITEDPOLYGRAPHICNETHERLANDSOther Sports
09/2025PLATINUM EQUITYXD CONNECTSNETHERLANDSConsumer Products
06/2025PARTNERS GROUPMPMUNITED KINGDOMPet Care
06/2025PLATINUM EQUITYSOLO GROUPFRANCEConsumer Products
06/2025KONTOOR BRANDSHELLY HANSENNORWAYFashion & Apparel
05/2025AUTHENTIC BRANDS GROUPDOCKERSUNITED STATESFashion & Apparel
04/2025BRICONORDSCELL-ITFRANCEHome & DIY
03/2025USHOPAL GROUPPAYOTFRANCEHygiene & Beauty Brands
02/2025BC PARTNERSPETLABUNITED KINGDOMPet Care
01/2025ACON INVESTMENTSTRUE RELIGIONUNITED STATESFashion & Apparel

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €450–900M

EBITDA range: €100–200M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Karo Healthcare by KKR are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers KKR’s acquisition of 100% of Karo Healthcare, a Swedish company specialised in Personal & Household, in 2025.

How was the acquisition of Karo Healthcare by KKR valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Karo Healthcare’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Karo Healthcare generated annual revenue estimated in the €450–900M range and EBITDA in the €100–200M bracket (FY 2024). Detailed financial figures are available to members.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.